TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32067048

Group type: EXPERIMENTAL
Intervention: DTaP-IPV-Hib and 13-valent pneumococcal conjugate vaccine (PCV13) concurrently, followed by 23-valent pneumococcal polysaccharide vaccine (PPV23) 2 months later.
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (immunocompetent children)
Number of subjects: 74
Study: 32067158

Group type: EXPERIMENTAL
Intervention: Lenvatinib
Number of subjects: 0
Study: 32067594

Group type: EXPERIMENTAL
Intervention: Non-contrast computed tomography-based IVT
Number of subjects: 229

Group type: COMPARATOR
Intervention: Control (non-thrombolyzed)
Number of subjects: 229
Study: 32067679

Group type: EXPERIMENTAL
Intervention: PIK3CA-mutated HR+/Her2- mBC
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: PIK3CA-mutated TNBC
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Residual PIK3CA mutations in plasma after chemotherapy
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: PIK3CA mutation distribution in mTNBC
Number of subjects: 649
Study: 32067683

Group type: EXPERIMENTAL
Intervention: pertuzumab + trastuzumab (HER2 alteration)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: pertuzumab + trastuzumab (HER2 mutation)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: vismodegib (PTCH-1 mutation)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: vemurafenib (BRAF mutation)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: atezolizumab (high TMB)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: chemotherapy-free regimens matched to specific molecular alterations
Number of subjects: 19
Study: 32067695

Group type: EXPERIMENTAL
Intervention: Optimal treatment of underlying conditions
Number of subjects: 0
Study: 32068113

Group type: EXPERIMENTAL
Intervention: Early localization of lesions in patients with biochemical recurrence of prostate cancer
Number of subjects: 0
Study: 32068685

Group type: EXPERIMENTAL
Intervention: Lower sedentary time
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Greater light physical activity
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Greater moderate-vigorous physical activity
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Greater vigorous physical activity
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Greater total physical activity
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Moderate physical activity
Number of subjects: 182
Study: 32068884

Group type: EXPERIMENTAL
Intervention: Targeted arterial oxygen tension of 8 kPa
Number of subjects: 2928

Group type: COMPARATOR
Intervention: Targeted arterial oxygen tension of 12 kPa
Number of subjects: 2928
Study: 32069106

Group type: EXPERIMENTAL
Intervention: 1-stent strategy for LM bifurcation lesions
Number of subjects: 2648

Group type: COMPARATOR
Intervention: 1-stent strategy for non-LM bifurcation lesions
Number of subjects: 2648
Study: 32069759

Group type: EXPERIMENTAL
Intervention: Cluster 1 (19.2% of participants) - users with combined potential psychological and social issues
Number of subjects: 2319

Group type: EXPERIMENTAL
Intervention: Cluster 2 (32.3% of participants) - users with potential social but no psychological issues
Number of subjects: 2319

Group type: COMPARATOR
Intervention: Cluster 3 (45.6% of participants) - users with no potential issues of either a social or psychological nature
Number of subjects: 2319
Study: 32070310

Group type: EXPERIMENTAL
Intervention: C. perfringens colonization
Number of subjects: 333

Group type: COMPARATOR
Intervention: Maternal milk feeds
Number of subjects: 333

Group type: COMPARATOR
Intervention: CPAP oxygen treatment
Number of subjects: 333

Group type: COMPARATOR
Intervention: Antibiotic treatment
Number of subjects: 333

Group type: COMPARATOR
Intervention: Bifidobacterium infantis
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Toxin gene screening
Number of subjects: 333
Study: 32070711

Group type: EXPERIMENTAL
Intervention: Endoscopic gastroplication
Number of subjects: 10
Study: 32071042

Group type: EXPERIMENTAL
Intervention: KBP-7072 (oral and intravenous formulations)
Number of subjects: 0
Study: 32071055

Group type: EXPERIMENTAL
Intervention: LPV/r-4:4 with rifampin
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: LPV/r-4:1 (1 month after treatment completion)
Number of subjects: 87
Study: 32071135

Group type: EXPERIMENTAL
Intervention: Automated oxygen titration to maintain stable oxygenation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Automated oxygen titration to correct hypoxemia
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oxygen delivery through a gas mask
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Optimized oxygen targets
Number of subjects: 60
Study: 32071189

Group type: EXPERIMENTAL
Intervention: Multidisciplinary mobile unit (MMU) team intervention delivering urgent care at the bedside.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (ED referral in every case of urgency).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MMU team intervention.
Number of subjects: 0
Study: 32071418

Group type: EXPERIMENTAL
Intervention: Ruxolitinib therapy in acute srGVHD
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Ruxolitinib therapy in chronic srGVHD
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Ruxolitinib therapy in both acute and chronic srGVHD
Number of subjects: 75
Study: 32071614

Group type: EXPERIMENTAL
Intervention: Supported self-management (SSM) intervention for 2 months, consisting of a workbook and supportive coaching.
Number of subjects: 376

Group type: COMPARATOR
Intervention: Enhanced treatment as usual (control) for 4 months, followed by SSM intervention.
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Supported self-management (SSM) intervention
Number of subjects: 376
Study: 32071868

Group type: EXPERIMENTAL
Intervention: Eunkyosan
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Samsoeum
Number of subjects: 375

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Eunkyosan or Samsoeum or Placebo
Number of subjects: 375
Study: 32072073

Group type: EXPERIMENTAL
Intervention: Knowledge translation (KT) intervention in 19 homes
Number of subjects: 5478

Group type: COMPARATOR
Intervention: Control group in 21 homes
Number of subjects: 5478

Group type: EXPERIMENTAL
Intervention: Zero inflated negative binomial method (primary approach)
Number of subjects: 5478

Group type: EXPERIMENTAL
Intervention: Generalized estimating equation (GEE) method
Number of subjects: 5478

Group type: EXPERIMENTAL
Intervention: Mixed-effects method
Number of subjects: 5478
Study: 32072130

Group type: EXPERIMENTAL
Intervention: Corn-Soy Blend Plus (CSB+) with fortified vegetable oil
Number of subjects: 6112

Group type: EXPERIMENTAL
Intervention: Corn-Soy-Whey Blend (CSWB) with oil
Number of subjects: 6112

Group type: EXPERIMENTAL
Intervention: SuperCereal Plus (SC+)
Number of subjects: 6112

Group type: EXPERIMENTAL
Intervention: Ready-to-use supplementary food (RUSF)
Number of subjects: 6112

Group type: COMPARATOR
Intervention: Control group (reference food)
Number of subjects: 6112
Study: 32072131

Group type: EXPERIMENTAL
Intervention: Whey protein isolate (WPI)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pea protein isolate (PPI)
Number of subjects: 30
Study: 32072161

Group type: EXPERIMENTAL
Intervention: Intravenous fish oil (FO) 1 g/kg/d
Number of subjects: 14
Study: 32072570

Group type: EXPERIMENTAL
Intervention: Exercise and diet intervention for 6 weeks
Number of subjects: 16
Study: 32073546

Group type: EXPERIMENTAL
Intervention: Neurodevelopmental assessments using instruments commonly used for early intervention screening in the community.
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Neurodevelopmental assessments focusing on motor, cognitive, and language development.
Number of subjects: 29

Group type: COMPARATOR
Intervention: Early intervention services.
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Multimethod approach to repeated assessments for young children with NPC1.
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Evaluation for early intervention services and consideration of investigational therapeutic interventions.
Number of subjects: 29
Study: 32073681

Group type: COMPARATOR
Intervention: GBA PD
Number of subjects: 599

Group type: COMPARATOR
Intervention: LRRK2 PD
Number of subjects: 599

Group type: COMPARATOR
Intervention: GBA PD and LRRK2 PD
Number of subjects: 599
Study: 32073954

Group type: EXPERIMENTAL
Intervention: Maintenance olaparib
Number of subjects: 2206
Study: 32074275

Group type: EXPERIMENTAL
Intervention: Azacitidine (AZA) at 75 mg/m2 subcutaneously or IV once daily on days 1 to 5 followed by HiDAC (3000 mg/m2) and mitoxantrone (30 mg/m2) once each on days 6 and 10.
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Azacitidine (AZA) at 50 mg/m2 (dose-limiting toxicities occurred).
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Azacitidine (AZA) at 37.5 mg/m2 (not specifically reported).
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Patients with favorable European Leukemia Network risk.
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Patients with NPM1 mutations.
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Patients with IDH2 mutations.
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Patients with TP53 mutations.
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 30-day induction death rate.
Number of subjects: 46
Study: 32074277

Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel infusion
Number of subjects: 115
Study: 32074665

Group type: EXPERIMENTAL
Intervention: Calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) foam applied once daily for ≤4 weeks
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) foam
Number of subjects: 106
Study: 32075470

Group type: EXPERIMENTAL
Intervention: Dupilumab, a monoclonal antibody targeting IL-4 and IL-13 signaling, specific dosage and duration not mentioned.
Number of subjects: 0
Study: 32075593

Group type: EXPERIMENTAL
Intervention: MAMAACT intervention (training course for midwives, leaflet, mobile application, additional visit time)
Number of subjects: 18
Study: 32075601

Group type: EXPERIMENTAL
Intervention: NASCITA cohort study
Number of subjects: 5000
Study: 32075647

Group type: EXPERIMENTAL
Intervention: Traditional Chinese version of the Resilience Scale-14
Number of subjects: 1816
Study: 32075790

Group type: EXPERIMENTAL
Intervention: Macrolide antibiotics during pregnancy (first trimester)
Number of subjects: 104605

Group type: EXPERIMENTAL
Intervention: Macrolide antibiotics during pregnancy (any trimester)
Number of subjects: 104605

Group type: COMPARATOR
Intervention: Penicillin antibiotics during pregnancy
Number of subjects: 104605
Study: 32075821

Group type: EXPERIMENTAL
Intervention: Clustering model with three clusters: 'Early Onset and Short Course' (47.5%), 'Early Onset and Long Course' (35%), 'Late Onset and Short Course' (17.5%).
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Gambling characteristics analysis.
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Simple screening based on gambling characteristics.
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Policy measures targeting gambling characteristics.
Number of subjects: 628
Study: 32075827

Group type: EXPERIMENTAL
Intervention: Clinicians
Number of subjects: 5155

Group type: COMPARATOR
Intervention: Revised Trauma Score (RTS)
Number of subjects: 5155

Group type: COMPARATOR
Intervention: Glasgow Coma Scale, Age and Systolic Blood Pressure (GAP) score
Number of subjects: 5155

Group type: COMPARATOR
Intervention: Kampala Trauma Score (KTS)
Number of subjects: 5155

Group type: COMPARATOR
Intervention: Gerdin
Number of subjects: 5155
Study: 32075841

Group type: EXPERIMENTAL
Intervention: GPs' sense of alarm (measured using the Gut Feelings Questionnaire)
Number of subjects: 235
Study: 32075847

Group type: EXPERIMENTAL
Intervention: Creation of urban trails (5-8 km long, paved, multiuse) built between 2008 and 2010.
Number of subjects: 0
Study: 32076124

Group type: EXPERIMENTAL
Intervention: AZD3965 (mono-carboxylase transporter 1 inhibitor)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Symptomatic treatment
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: FDG-PET scan
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Literature review
Number of subjects: 1
Study: 32076473

Group type: EXPERIMENTAL
Intervention: Post-dilatation (non-compliant balloon inflated to >16 atm pressure)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no post-dilatation)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Post-dilatation
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study: 32076567

Group type: EXPERIMENTAL
Intervention: Non-compliant balloons (NCBs)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Semi-compliant balloons (SCBs)
Number of subjects: 104
Study: 32076579

Group type: EXPERIMENTAL
Intervention: pembrolizumab
Number of subjects: 91
Study: 32076889

Group type: EXPERIMENTAL
Intervention: Dotinurad (4 mg) with oxaprozin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Dotinurad (4 mg) alone
Number of subjects: 12
Study: 32077361

Group type: EXPERIMENTAL
Intervention: Sequential ('primed') decitabine in combination with CLAG-M
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concurrent decitabine in combination with CLAG-M
Number of subjects: 0
Study: 32077442

Group type: EXPERIMENTAL
Intervention: Higher social anxiety in adolescents less than 13 years of age
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adolescents aged 13 and older
Number of subjects: 0
Study: 32077603

Group type: EXPERIMENTAL
Intervention: pegylated-interferon (PEG-IFN) for 48 weeks
Number of subjects: 15000000

Group type: EXPERIMENTAL
Intervention: bulevirtide (entry inhibitor)
Number of subjects: 15000000

Group type: EXPERIMENTAL
Intervention: lonafarnib (prenylation inhibitor)
Number of subjects: 15000000

Group type: EXPERIMENTAL
Intervention: REP 2139 (HBsAg release inhibitor)
Number of subjects: 15000000
Study: 32077779

Group type: EXPERIMENTAL
Intervention: Allogenic transplantation of limbal stem cells expanded on amniotic membrane
Number of subjects: 0
Study: 32077895

Group type: EXPERIMENTAL
Intervention: Trabectedin (1.3 mg/m2 starting dose, 1.5 mg/m2 dose level +1, 1.1 mg/m2 dose level -1) plus radiotherapy (30 Gy, 3 Gy/d for 10 days)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Trabectedin (1.3 mg/m2 starting dose, 1.5 mg/m2 dose level +1, 1.1 mg/m2 dose level -1)
Number of subjects: 45
Study: 32077948

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT) for women
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT) for men
Number of subjects: 251
Study: 32078016

Group type: EXPERIMENTAL
Intervention: DC vaccines transfected with personalized TAA panels
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low-dose cyclophosphamide, poly I:C, imiquimod and anti-PD-1 antibody (in combination with DC vaccines)
Number of subjects: 10
Study: 32078124

Group type: EXPERIMENTAL
Intervention: Split first dose of intravenous daratumumab (16 mg/kg split into two 8 mg/kg doses on Days 1 and 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single first dose of intravenous daratumumab (16 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Split first dose of intravenous daratumumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single first dose of intravenous daratumumab
Number of subjects: 0
Study: 32078362

Group type: EXPERIMENTAL
Intervention: LICU system
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: LICU system with enhanced software
Number of subjects: 52
Study: 32078381

Group type: EXPERIMENTAL
Intervention: Increased maternal systolic blood pressure
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Increased maternal diastolic blood pressure
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Increased maternal systolic and diastolic blood pressure
Number of subjects: 301
Study: 32078781

Group type: EXPERIMENTAL
Intervention: Human milk feeding
Number of subjects: 24113

Group type: EXPERIMENTAL
Intervention: Exclusive human milk feeding
Number of subjects: 24113

Group type: EXPERIMENTAL
Intervention: Human milk feeding rates
Number of subjects: 24113

Group type: EXPERIMENTAL
Intervention: Human milk feeding practices
Number of subjects: 24113

Group type: EXPERIMENTAL
Intervention: Human milk feeding rates over time
Number of subjects: 24113
Study: 32078808

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32078813

Group type: EXPERIMENTAL
Intervention: Cabozantinib (adults 60 mg, children <16 years 40 mg)
Number of subjects: 90
Study: 32079476

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 6784

Group type: EXPERIMENTAL
Intervention: Modifiable bleeding risk factors (heavy alcohol use, uncontrolled hypertension, concomitant treatment with antiplatelets, NSAIDs, or paracetamol)
Number of subjects: 6784

Group type: EXPERIMENTAL
Intervention: Nonmodifiable bleeding risk factors (increasing age, heart failure, vascular disease)
Number of subjects: 6784
Study: 32079557

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 287079

Group type: COMPARATOR
Intervention: Nicotine Replacement Therapy
Number of subjects: 287079
Study: 32079624

Group type: EXPERIMENTAL
Intervention: 12 months of adjuvant trastuzumab
Number of subjects: 11250

Group type: COMPARATOR
Intervention: Shorter trastuzumab regimens
Number of subjects: 11250
Study: 32079690

Group type: EXPERIMENTAL
Intervention: Immunochemotherapy with focus on T-cell immune checkpoint molecules
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: TME immune cell signature
Number of subjects: 188
Study: 32079702

Group type: EXPERIMENTAL
Intervention: ctDNA analysis after 2 cycles of chemotherapy (C2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ctDNA analysis at diagnosis
Number of subjects: 60
Study: 32079709

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PARP inhibitors (olaparib, niraparib, rucaparib)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Homologous recombination repair deficiency
Number of subjects: 0
Study: 32080086

Group type: EXPERIMENTAL
Intervention: Polymer-free sirolimus eluting stents (PF-SES)
Number of subjects: 7243
Study: 32080135

Group type: EXPERIMENTAL
Intervention: Salt substitute with 18% sodium chloride for 8 weeks
Number of subjects: 43
Study: 32080210

Group type: EXPERIMENTAL
Intervention: Vorinostat combined with ixazomib
Number of subjects: 70

Group type: COMPARATOR
Intervention: Vorinostat combined with pazopanib
Number of subjects: 70
Study: 32080720

Group type: EXPERIMENTAL
Intervention: Aerobic and Resistance Training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 32080809

Group type: EXPERIMENTAL
Intervention: Individualized web-based recurrence risk assessment tool
Number of subjects: 8249
Study: 32081289

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ezetimibe/Simvastatin
Number of subjects: 0
Study: 32082310

Group type: EXPERIMENTAL
Intervention: Complement activation assessment
Number of subjects: 0
Study: 32082606

Group type: EXPERIMENTAL
Intervention: Oral probiotics
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 60
Study: 32083013

Group type: EXPERIMENTAL
Intervention: Adjuvant Immunotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 32083104

Group type: EXPERIMENTAL
Intervention: Equine-Assisted Activities and Brain-Building Activities (GaitWay block)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Equine-Assisted Activities only
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control
Number of subjects: 25

Group type: COMPARATOR
Intervention: Washout
Number of subjects: 25
Study: 32083219

Group type: EXPERIMENTAL
Intervention: Orientation sessions implemented before informed consent and randomization
Number of subjects: 467

Group type: COMPARATOR
Intervention: Before orientation sessions
Number of subjects: 467
Study: 32083583

Group type: EXPERIMENTAL
Intervention: Carotid β stiffness index
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Carotid distensibility
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: cfPWV
Number of subjects: 32
Study: 32083996

Group type: EXPERIMENTAL
Intervention: Bendamustine with dexamethasone (ben-dex)
Number of subjects: 31
Study: 32084260

Group type: EXPERIMENTAL
Intervention: ASTCT grading system for CRS
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: ASTCT grading system for ICANS
Number of subjects: 102

Group type: COMPARATOR
Intervention: Comparison of grading systems for CRS
Number of subjects: 102

Group type: COMPARATOR
Intervention: Comparison of grading systems for ICANS
Number of subjects: 102

Group type: COMPARATOR
Intervention: Grade comparison for CRS
Number of subjects: 102

Group type: COMPARATOR
Intervention: Grade comparison for ICANS
Number of subjects: 102
Study: 32084274

Group type: EXPERIMENTAL
Intervention: Suction cup method to increase IOP
Number of subjects: 15
Study: 32084409

Group type: EXPERIMENTAL
Intervention: Ad5-DS (adenovirus-mediated double-suicide gene therapy) injected into pancreatic mass with EUS-guided fine needles, combined with oral 5-fluorocytosine and valganciclovir, and standard dose of intravenous gemcitabine.
Number of subjects: 11
Study: 32085707

Group type: EXPERIMENTAL
Intervention: CHW-delivered intervention
Number of subjects: 105
Study: 32085865

Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 2240

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting
Number of subjects: 2240
Study: 32085891

Group type: EXPERIMENTAL
Intervention: Lurbinectedin monotherapy, administered intravenously at 3.2 mg/m²
Number of subjects: 42
Study: 32085892

Group type: EXPERIMENTAL
Intervention: Adjuvant FOLFOX or FLOX (2004-2009)
Number of subjects: 6501

Group type: COMPARATOR
Intervention: Adjuvant FOLFOX or FLOX (1998-2003)
Number of subjects: 6501
Study: 32086343

Group type: EXPERIMENTAL
Intervention: Toripalimab (3 mg/kg once every two weeks)
Number of subjects: 40
Study: 32086361

Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention using the Drug Burden Index (DBI) Calculator
Number of subjects: 160

Group type: COMPARATOR
Intervention: Preintervention retrospective control cohort
Number of subjects: 160
Study: 32086522

Group type: COMPARATOR
Intervention: Conventional IVF
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ICSI
Number of subjects: 30
Study: 32086697

Group type: EXPERIMENTAL
Intervention: Proton therapy (double-scattered conformal proton therapy) to a mean dose of 54 GyRBE in 1.8 GyRBE/fraction (range 52.2-54 GyRBE)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Proton therapy (double-scattered conformal proton therapy)
Number of subjects: 14